Recommendations by the Swedish lung cancer group. Shorter waiting time is a quality requirement in the management of lung cancer
Hillerdal, G.
Lakartidningen 96(43): 4691
1999
ISSN/ISBN: 0023-7205 PMID: 10575882 Document Number: 501611
Document emailed within 1 workday
Related Documents
Levin, W.J.; Press, M.F.; Gaynor, R.B.; Sukhatme, V.P.; Boone, T.C.; Reissmann, P.T.; Figlin, R.A.; Holmes, E.C.; Souza, L.M.; Slamon, D.J. 1995: Expression patterns of immediate early transcription factors in human non-small cell lung cancer. the Lung Cancer Study Group Oncogene 11(7): 1261-1269Perng, R.P.; Chien, K.Y.; Chen, K.Y. 1989: Combined modality treatment for non-small cell lung cancer. Lung Cancer Study Group Zhonghua Yi Xue Za Zhi 43(4): 217-222
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Pedersen, J.H.; Saghir, Z.; Wille, M.M.W.; Thomsen, L.H.ü; Skov, B.G.; Ashraf, H. 2016: Ground-Glass Opacity Lung Nodules in the Era of Lung Cancer CT Screening: Radiology, Pathology, and Clinical Management Oncology 30(3): 266-274
Luikart, S.D.; Propert, K.J.; Modeas, C.R.; Green, M.R.; Perry, M.C. 1987: High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study Cancer Treatment Reports 71(5): 533-534
1989: Diagnosis and first-line treatment of patients with lung cancer in Italian general hospitals. G.I.V.I.O. (Interdisciplinary Group for Cancer Evaluation) Tumori 75(2): 163-167
McCormack, V.A.; Hung, R.J.; Brenner, D.R.; Bickeböller, H.; Rosenberger, A.; Muscat, J.E.; Lazarus, P.; Tjønneland, A.; Friis, Søren.; Christiani, D.C.; Chun, E-Mi.; Le Marchand, L.; Rennert, G.; Rennert, H.S.; Andrew, A.S.; Orlow, I.; Park, B.; Boffetta, P.; Duell, E.J. 2011: Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO) Cancer Causes and Control: Ccc 22(12): 1709-1720
Evans, W.K. 1997: Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module Seminars in Oncology 24(2 Suppl 7: S7
Miyamoto, T.; Inoue, M.; Tanemura, M.; Yamaguchi, M.; Irei, T.; Tamaru, K.; Seo, S.; Misumi, T.; Shimizu, W.; Suzuki, T.; Onoe, T.; Sudo, T.; Shimizu, Y.; Hinoi, T.; Tashiro, H. 2018: A Resectable Case of TS-1 Therapy Useful in Distinguishing Primary Lung Cancer from Lung Metastases of Pancreatic Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(1): 88-90
El-Akawi, Z.J.; Nusier, M.K.; Zoughool, F.E. 2006: Relationship between alpha-1 antitrypsin deficient genotypes S and Z and lung cancer in Jordanian lung cancer patients Saudi Medical Journal 27(2): 181-184
Barlow, L.; Einhorn, J.; Eklund, G.; Ericsson, A.; Ericson, J. 1994: Is the incidence of lung cancer among Swedish men decreasing? Distinct differences between big cities and countryside Lakartidningen 91(14): 1398; 1401-1403
O'Rourke, M.A.; Feussner, J.R.; Feigl, P.; Laszlo, J. 1987: Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly JAMA 258(7): 921-926
Schreiber, G.; Pitterle, D.; Kim, Y.C.; Bepler, G. 1999: Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung Anticancer Research 19(2a): 1109-1115
Hijmering-Kappelle, L.B.M.; van der Wekken, A.J.; Hiltermann, T.J.N.; Groen, H.J.M. 2017: New biopsy at lung cancer progression: rational treatment of resistant lung cancer Nederlands Tijdschrift Voor Geneeskunde 161: D1229
Dhabhar, B.N.; Malhotra, H.; Advani, S.H. 1992: Incidence of lung cancer and advances in non-small cell lung cancer Journal of the Association of Physicians of India 40(7): 493
Thongprasert, S.; Intarapak, S.; Saengsawang, P.; Thaikla, K. 2005: Reliability of the Thai-modified Function Living Index Cancer questionnaire version 2 (T-FLIC 2) for the evaluation of quality of life in non-small cell lung cancer patients Journal of the Medical Association of Thailand 88(12): 1809-1815
Balaton, A.L.; Coindre, J.M.; Collin, F.; Ettore, F.; Fiche, M.; Jacquemier, J.; Le Doussal, V.; Mandard, A.M.; Mathieu, M.C.; Migeon, C.; Simony-Lafontaine, J.; Treilleux, I.; Verriele, V.; Vilain, M.O.; Zafrani, B. 1996: Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology Annales de Pathologie 16(2): 144-148
Kimura, I.; Ohnoshi, T.; Nakata, Y.; Nakata, Y.; Hiraki, S.; Miyake, K. 1980: Lung cancer: problems in the treatment of advanced lung cancer Nihon Kyobu Shikkan Gakkai Zasshi 18(9): 572-577
Kuwahara, T. 1986: Cytodiagnosis of lung cancer. Immunohistochemical findings in lung cancer Rinsho Byori. Japanese Journal of Clinical Pathology 34 Spec no 66: 163-174
Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12